HCV Advocate Newsletter: 2017
This site includes links to files you can view online or print. To download and print information, you will need the latest version of Adobe Acrobat Reader. Download it free.
- Lucinda’s Highlights from ILC 2017: Marijuana and liver transplant waitlist; expanding age-based testing; health-related quality of life and children treated with sofosbuvir and ribavirin; the effect of cholesterol and low-density lipoprotein after DAA treatment, and cardiovascular and cerebrovascular effects after DAA therapy.
- Alan’s Highlight’s from ILC 2017: Prevalence of concomitant substance abuse and mental health disorders in a HCV treatment program; factors associated with spontaneous viral clearance; treatment of acute HCV in people with HIV; treatment of HCV in New Mexico prison using telemedicine.
- Matthew’s Highlight’s from ILC 2017: Group medical intervention to improve HCV uptake among PWIDs in a primary care setting; 4 weeks of DAA treatment + ribavirin +/- pegylated interferon to treat PWIDs; evaluation of homeless on HCV treatment among PWIDs.
- Monday June 5th – Vestavia, Alabama
- Wednesday June 7th –Montgomery, Alabama
We have added a voiceover feature to some of our Easy C Fact Sheets:
What are Ravs / Viral Load Test / Taking HCV Meds / Ribavirin Warning
Hepatitis B Warning / Hepatitis C Antibody Test / Drug Resistance\What is HCV Genotype?
What is ALT? / What is Subtype?
Instructions on how to listen to the voiceovers are included on an overview website page (here). I would be very interested in feedback from our readers on the current voiceovers and recommendations for voiceovers on other fact sheets. Thank You!
- HealthWise – Sleep: The Key to a Healthy Liver by Lucinda K. Porter, RN. In this month’s column Lucinda explores the connection between sleep, the liver, a person’s health and the dreaded daylight saving time.
- SnapShots—by Alan Franciscus. I discuss three studies: Zepatier to treat people with bleeding disorders, the transformation of HCV treatment from the interferon era to direct-acting antiviral era with the VA system and finally the incidence of fatty liver in people with HIV, HCV, HIV/HCV coinfection and those with neither—and the very surprising outcome from the study.
- Under the Umbrella—Five Ways Hepatitis C is Unique to Women by Matthew Zielske. Matthew lays out five important facts about women and hepatitis C that you may or may not know about women infected with hepatitis C.
- What’s Up!
- HealthWise – Why We Need to Treat Everyone Who Has Hepatitis C by Lucinda K. Porter, RN – Lucinda explores how to eliminate hepatitis C in this thought-provoking article.
- Under The Umbrella—The Pros and Cons of Learning about Hepatitis C on the Internet by Matthew Zielske—Matthew writes about the pros and cons of educating ourselves and others about hepatitis C on the internet.
- SnapShots by Alan Franciscus.In this month’s column I write about three studies—the new liver chemistry guidelines issued, potential liver injury from herbal and dietary supplements, and an analysis about the treatment using Zepatier in people with compensated cirrhosis.
- The Drug Pipeline has been pretty quiet this month with the exception of the news that AbbVie’s two drug combination of glecaprevir plus pibrentasvir to treat all genotypes (pan-genotypic) had been granted a FDA priority review-meaning that the drug approval process will be speeded up.
- What’s Up! – In this month notice we have updated the following fact sheets:
- HealthWise – Connecting the Heart and the Liver – Lucinda K. Porter, RN. Lucinda talks about the health of these important organs. The number of people who die from heart disease annually is staggering.
- Under The Umbrella—Harm Reduction and Hepatitis C – Matthew Zielske.Matthew discusses aspects of harm reduction geared towards hepatitis C transmission. He is also working on many new Harm Reduction fact sheets for the HCV Advocate Website. Three new fact sheets are listed below.
- SnapShots – Alan Franciscus. In this month’s column I cover three studies—deaths caused by hepatitis C among Mexican Americans, non-Hispanics Whites and non-Hispanic Blacks, the changes in the most common indications for liver transplants and transplant waitlists and finally, a study that looked at the best practice to screen people at risk (including Baby Boomers) for hepatitis C in an effort to increase screening. All three studies are very illuminating.
- Drug Pipeline — no changes in this month’s Drug Pipeline
- What’s Up! – New this month are three Harm Reduction Fact Sheets:
- Harm Reduction and Alcohol
- Harm Reduction and Indirect Sharing
- Harm Reduction Definitions
- Coming Mid-February: Hepatitis C Drug Pipeline and Conference Coverage – The new feature will be populated by our conference coverage from 2016, from EASL and AASLD, and future conferences as well as current and future articles about drugs in development.
- 2016 In Review: Check out what our staff picked as the top news of last year.
- Under the Umbrella – The Art of Seeing by Matthew Zielske—Matthew discusses the meaning of being an advocate – an inspiring article to bring in 2017
- HealthWise by Lucinda K. Porter RN – Lucinda writes and argues for the elimination of hepatitis C in the United States and globally.
- AASLD 2016 – Part 2 by Alan Franciscus-I write about drugs in development to treat hepatitis C, monitoring people who are at risk for liver cancer and treating hepatitis C in people who inject drugs.
- HCV Advocate Pipeline
- What’s Up!
- Paper PI – we have decided to close down the Paper PI newsletter since we cover all the news in our News and Pipeline Blog.
- HCV and Harm Reduction – we have launched a new series of fact sheets on Harm Reduction. The first piece is an Overview of Harm Reduction by Matthew Zielske.
- Easy C Fact Sheet – Hep C Prevention in a Household – A common concern for people living together. This simple fact sheet provides information on how to stay safe
- Easy C Fact Sheet – Beware of Hepatitis B – we have revised this fact sheet based on feedback. The actual cases of HBV reactivation are uncommon and occurred with pegylated interferon therapies and the new direct-acting antiviral therapies.